Replies to post #142805 on Biotech Values

[genisi]

I found the data from phase II of the two BRAF inhibitors and with the caveat of comparing results from different trials, they seem to be in the same ballpark.

BRIM2 phase II data for Zelboraf (vemurafenib)

http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=84075

BRF113710 phase II study of dabrafenib (GSK2118436)

http://www.gsk-clinicalstudyregister.com/result_comp_list.jsp?phase=Phase+2&studyType=All&population=All&marketing=All&compound=dabrafenib

[genisi]

Looking at data from GSK's dabrafenib monotherapy in phase III melanoma trial, efficacy seems similar to that of Zelboraf but AEs seem better.

http://abstract.asco.org/AbstView_114_96291.html